We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner. In this article, we will summarize the bulls thesis on RLAY. Relay Therapeutics, Inc. (RLAY)'s share wa… [+3631 chars]...
Read moreRelay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) – Equities researchers at HC Wainwright raised their Q2 2025 earnings per share estimates for shares of Relay Therapeutics in a research note issu… [+6261 chars]...
Read moreRelay Therapeutics (NASDAQ:RLAY – Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Relay Therapeutics to… [+4358 chars]...
Read moreCAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-… [+1166 chars]...
Read moreWe recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other best lo… [+146 chars]...
Read moreFederated Hermes Inc. lifted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 536.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 50,100 shares of the compan… [+5627 chars]...
Read more